Armata Pharmaceuticals (ARMP) Other Accumulated Expenses (2016 - 2026)

Armata Pharmaceuticals has disclosed Other Accumulated Expenses across 6 years of filings, most recently posting $372000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $372000.0, up 10.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $372000.0 (up 10.39% YoY), and the FY2025 annual result was $487000.0, down 7.94% from the prior year.
• Other Accumulated Expenses came in at $372000.0 for Q1 2026 at Armata Pharmaceuticals, down from $487000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $529000.0 in Q4 2024 to a low of $124000.0 in Q2 2024.
• The 4-year median for Other Accumulated Expenses is $429500.0 (2025), against an average of $384700.0.
• Peak annual rise in Other Accumulated Expenses reached 10.48% in 2025, while the deepest fall reached 7.94% in 2025.
• Armata Pharmaceuticals' Other Accumulated Expenses stood at $523000.0 in 2023, then rose by 1.15% to $529000.0 in 2024, then declined by 7.94% to $487000.0 in 2025, then retreated by 23.61% to $372000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $372000.0 (Q1 2026), $487000.0 (Q4 2025), and $503000.0 (Q3 2025), per Business Quant data.